ArticleInternational ophthalmology2025
An examination of the ocular effects of methylphenidate used in children and adolescents diagnosed with attention-deficit hyperactivity disorder.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ocular structural parameters in children with attention-deficit/hyperactivity disorder: a case-control study of drug-naïve and methylphenidate-treated patients.BMC ophthalmology · 2026Article
- Alterations in Corneal Morphology and Thickness Associated with Methylphenidate Treatment in Children with Attention-Deficit/Hyperactivity Disorder.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION-
aimTo examine the ocular effects of methylphenidate used in children and adolescents diagnosed with attention-deficit hyperactivity disorder (ADHD).
methodChildren diagnosed with ADHD and healthy control children were included in the study. The cases were divided into three groups-those with attention-deficit and hyperactivity and receiving methylphenidate therapy (Group 1), newly diagnosed cases not using medication (Group 2), and healthy, control group children (Group 3), and the results obtained were compared between them. The morphology and numbers of corneal endothelial cells, corneal thickness, choroidal thickness (CT), retinal thickness (RT), the ganglion cell layer (GCL), and retina nerve fiber layer were evaluated.
resultsThirty children diagnosed with ADHD and receiving methylphenidate therapy for at least one year (Group 1), 32 children newly diagnosed with ADHD and not started on medication (Group 2), and a control group of 35 healthy children (Group 3) were included in the study. Mean ages were 10.53 ± 2.78 years in Group 1, 9.21 ± 1.85 in Group 2, and 11.03 ± 3.01 in Group 3. No statistically significant differences were observed among the three groups in terms of age, visual acuity, or refraction values (p > 0.05). However, significant differences were determined in endothelial cell counts and hexagonality values between groups 1 and 2 (p = 0.041 and p = 0.031, respectively). No significant difference was observed among the three groups in terms of central CT, central RT, or mean RNFL values (p > 0.05). However, GCL values differed between groups 1 and 2 and between groups 2 and 3 (p = 0.0001 and p = 0.02, respectively), but no significant difference was observed between groups 1 and 3 (p = 0.551).
conclusionCorneal endothelial counts were lower in the children diagnosed with ADHD and receiving methylphenidate therapy than in those not receiving treatment and the control group. In addition, GCL measurements were lower in the children diagnosed with ADHD and not using medication compared to those using methylphenidate and the control group.
Indexed as
Identifiers
40085168What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.